Medicxi

Activities: Finance Pharmaceutical

Trending Articles

  1. IMPACT CKD model reveals the escalating toll of chronic kidney disease The model projects up to 125 million of the population across eight countries to suffer from chronic kidney disease by 2032
  2. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  3. Isospec Analytics launches biomolecular analysis technology to identify unknown molecules The novel technology optimises the identification process of unknown molecules compared to mass analysis
  4. Building strong foundations for a resilient and planet-friendly future Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI...
  5. ten23 health and Ypsomed collaborate to commercialise the YpsoDose patch injector The partnership will bring the drug delivery device to the pharmaceutical market quicker, whilst reducing development risks

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Manufacturing

Lilly set to acquire Versanis Bio to "improve patient outcomes in cardiometabolic diseases"

Under the terms of the agreement, which is subject to customary conditions, Versanis shareholders would receive up to $1.925 billion USD in cash
Research & Development

Sosei Heptares announces €40 million Medicxi investment

Two asset-centric companies have been formed to develop Sosei’s novel therapies for neurological diseases funded by Medicxi
Research & Development

Moncef Slaoui joins Medicxi
Research & Development

Medicxi launches first $300m late-stage life sciences fund: Medicxi Growth 1

Novartis’ backing adds further validation to the Medicxi investment strategy
Subscribe now